Overview

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
Phase:
PHASE2
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.